
    
      Study design:

      This is a Phase II single arm open label study evaluating 10 mg Montelukast given at least 2
      hours prior to infusion of monoclonal antibody in addition to standard premedication.
      Monoclonal antibodies being evaluated include those commonly used to treat hematologic and
      oncologic malignancies like (Blinatumomab, Daratumumab, Elotuzumab, Gemtuzumab, Obinutuzumab,
      and Rituximab).

      Arms/Intervention; Study subjects will be given 10 mg of Montelukast to be orally
      self-administered at least 2 hours prior to beginning of chemotherapy section Standard
      premedication will be administered according to institution protocol
    
  